Mary Jo Turk

7.3k total citations · 2 hit papers
67 papers, 5.7k citations indexed

About

Mary Jo Turk is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Mary Jo Turk has authored 67 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Immunology, 43 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Mary Jo Turk's work include Immunotherapy and Immune Responses (37 papers), Cancer Immunotherapy and Biomarkers (28 papers) and T-cell and B-cell Immunology (28 papers). Mary Jo Turk is often cited by papers focused on Immunotherapy and Immune Responses (37 papers), Cancer Immunotherapy and Biomarkers (28 papers) and T-cell and B-cell Immunology (28 papers). Mary Jo Turk collaborates with scholars based in United States, United Kingdom and Japan. Mary Jo Turk's co-authors include Philip S. Low, Christopher P. Leamon, Jeffrey D. Lewis, Nikki Parker, Elaine Westrick, Alan N. Houghton, José A. Guevara-Patiño, Gabrielle Rizzuto, Manuel E. Engelhorn and Katelyn T. Byrne and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Mary Jo Turk

63 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay

2005 1.0k citations Mary Jo Turk et al. profile →
IL-35-mediated induction of a potent regulatory T cell population

2010 676 citations Lauren W. Collison, Vandana Chaturvedi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mary Jo Turk United States	35	3.0k	2.2k	1.6k	711	696	67	5.7k
Xue‐Feng Bai United States	41	2.7k 0.9×	1.3k 0.6×	1.2k 0.7×	660 0.9×	182 0.3×	123	4.8k
Yandan Yao China	37	1.7k 0.6×	1.4k 0.6×	4.5k 2.8×	779 1.1×	511 0.7×	77	7.1k
Christina Pfirschke United States	18	2.5k 0.8×	1.8k 0.8×	1.4k 0.9×	824 1.2×	492 0.7×	20	4.3k
Nadia Carlesso United States	32	1.1k 0.4×	973 0.4×	2.7k 1.7×	538 0.8×	523 0.8×	65	5.5k
W. Joost Lesterhuis Australia	39	4.2k 1.4×	3.5k 1.6×	1.9k 1.2×	665 0.9×	363 0.5×	86	6.7k
Reinhard Ebner United States	22	1.8k 0.6×	2.1k 0.9×	3.5k 2.2×	1.5k 2.1×	287 0.4×	27	6.9k
Margareta M. Mueller Germany	31	972 0.3×	1.7k 0.8×	1.8k 1.1×	802 1.1×	345 0.5×	48	4.6k
Pedro Berraondo Spain	36	3.3k 1.1×	2.9k 1.3×	1.8k 1.1×	463 0.7×	155 0.2×	164	5.9k
Domingo F. Barber Spain	39	2.4k 0.8×	754 0.3×	1.1k 0.7×	810 1.1×	754 1.1×	82	4.4k
Gabriele Niedermann Germany	34	1.6k 0.5×	1.9k 0.8×	2.0k 1.3×	504 0.7×	113 0.2×	81	4.7k

Countries citing papers authored by Mary Jo Turk

Since Specialization

Citations

This map shows the geographic impact of Mary Jo Turk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Jo Turk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Jo Turk more than expected).

Fields of papers citing papers by Mary Jo Turk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Jo Turk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Jo Turk. The network helps show where Mary Jo Turk may publish in the future.

Co-authorship network of co-authors of Mary Jo Turk

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Jo Turk. A scholar is included among the top collaborators of Mary Jo Turk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Jo Turk. Mary Jo Turk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Peck, Michael A., et al.. (2025). CD4 T cell depletion increases memory differentiation of endogenous and CAR T cells and enhances the efficacy of Super2 and IL-33-armored CAR T cells against solid tumors. Journal for ImmunoTherapy of Cancer. 13(2). e009994–e009994. 4 indexed citations

Searles, Tyler G., Chun‐Chieh Lin, Keisuke Shirai, et al.. (2024). CD39 Is Expressed on Functional Effector and Tissue-resident Memory CD8+ T Cells. The Journal of Immunology. 213(5). 588–599. 4 indexed citations

Sinicrope, Frank A. & Mary Jo Turk. (2024). Immune checkpoint blockade: timing is everything. Journal for ImmunoTherapy of Cancer. 12(8). e009722–e009722. 5 indexed citations

Vella, Jennifer L., Aleksey Molodtsov, Christina V. Angeles, et al.. (2021). Dendritic cells maintain anti-tumor immunity by positioning CD8 skin-resident memory T cells. Life Science Alliance. 4(10). e202101056–e202101056. 29 indexed citations

Sanseviero, Emilio, Erin M. O’Brien, Tamer B. Shabaneh, et al.. (2019). Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control. Cancer Immunology Research. 7(8). 1371–1380. 51 indexed citations

Shabaneh, Tamer B., Aleksey Molodtsov, Shannon M. Steinberg, et al.. (2018). Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis. Cancer Research. 78(17). 5038–5049. 77 indexed citations

Zhao, Yanding, Evelien Schaafsma, Eva Hernando, et al.. (2018). A Leukocyte Infiltration Score Defined by a Gene Signature Predicts Melanoma Patient Prognosis. Molecular Cancer Research. 17(1). 109–119. 22 indexed citations

Padrón, Álvaro, Vincent Hurez, Harshita B. Gupta, et al.. (2018). Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model. Experimental Gerontology. 105. 146–154. 33 indexed citations

Yan, Shaofeng, Zhongze Li, Jan L. Fisher, et al.. (2018). VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival. Cancer Immunology Immunotherapy. 67(7). 1113–1121. 90 indexed citations

10.

Steinberg, Shannon M., Tamer B. Shabaneh, Peisheng Zhang, et al.. (2017). Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors. Cancer Research. 77(7). 1599–1610. 79 indexed citations

11.

Malik, Brian T., Katelyn T. Byrne, Jennifer L. Vella, et al.. (2017). Resident memory T cells in the skin mediate durable immunity to melanoma. Science Immunology. 2(10). 201 indexed citations

12.

Li, Na, Wenwen Xu, Ying Yuan, et al.. (2017). Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis. Scientific Reports. 7(1). 1485–1485. 79 indexed citations

13.

Clark, Curtis A., Harshita B. Gupta, Gangadhara R. Sareddy, et al.. (2016). Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. Cancer Research. 76(23). 6964–6974. 309 indexed citations

14.

Clancy‐Thompson, Eleanor, Walburga Croteau, Matthew P. Alexander, et al.. (2015). Melanoma Induces, and Adenosine Suppresses, CXCR3-Cognate Chemokine Production and T-cell Infiltration of Lungs Bearing Metastatic-like Disease. Cancer Immunology Research. 3(8). 956–967. 34 indexed citations

15.

Steinberg, Shannon M., Peisheng Zhang, Brian T. Malik, et al.. (2014). BRAF Inhibition Alleviates Immune Suppression in Murine Autochthonous Melanoma. Cancer Immunology Research. 2(11). 1044–1050. 57 indexed citations

16.

Guo, Yanxia, Karina Pino‐Lagos, Kathy A. Bennett, et al.. (2012). A Retinoic Acid—Rich Tumor Microenvironment Provides Clonal Survival Cues for Tumor-Specific CD8+ T Cells. Cancer Research. 72(20). 5230–5239. 37 indexed citations

17.

Collison, Lauren W., Abigail Henderson, Vandana Chaturvedi, Mary Jo Turk, & Dario A.A. Vignali. (2010). Interleukin-35-mediated induction of a novel regulatory T cell population (49.7). The Journal of Immunology. 184(Supplement_1). 49.7–49.7. 1 indexed citations

18.

Uchi, Hiroshi, Rodica Stan, Mary Jo Turk, et al.. (2006). Unraveling the Complex Relationship Between Cancer Immunity and Autoimmunity: Lessons from Melanoma and Vitiligo. Advances in immunology. 90. 215–241. 54 indexed citations

19.

Cohen, Adam D., Adi Diab, Miguel‐Angel Perales, et al.. (2006). Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity. Cancer Research. 66(9). 4904–4912. 165 indexed citations

20.

Ramirez‐Montagut, Teresa, Mary Jo Turk, Jedd D. Wolchok, José A. Guevara-Patiño, & Alan N. Houghton. (2003). Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene. 22(20). 3180–3187. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact